Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 18f-bay94-9172
2. 18f-florbetaben
3. 4-(n-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
4. Bay 94-9172
5. Bay94 9172
6. Bay94-9172
7. Florbetaben
1. Neuraceq
2. Florbetaben (18f)
3. Florbetaben F18
4. Florbetaben
5. Florbetaben F 18
6. 18f-florbetaben
7. Unii-tla7312toi
8. 902143-01-5
9. Florbetaben ((sup 18)f)
10. Florbetaben (18f) [inn]
11. Bay94-9172
12. Bay 94-9172
13. Chebi:79033
14. Florbetaben F18 [usan]
15. Bay-949172
16. 18f-bay94-9172
17. Tla7312toi
18. Av-1
19. 4-((1e)-2-(4-(2-(2-(2-((sup 18(f))fluoroethoxy)ethoxy)ethoxy)phenyl)eth-1-en-1-yl)-n-methylaniline
20. 4-[(e)-2-[4-[2-[2-(2-(18f)fluoranylethoxy)ethoxy]ethoxy]phenyl]ethenyl]-n-methylaniline
21. Neuraceq (tn)
22. Florbetaben ((18)f)
23. Florbetaben 18f [inn]
24. Florbetaben (f-18)
25. Chembl566752
26. Gtpl7769
27. Schembl11301755
28. Florbetaben F 18 [mi]
29. Dtxsid20238065
30. Florbetaben(18f) [jan]
31. Bdbm50485236
32. Florbetaben (18f) [who-dd]
33. Bay94 9172
34. Db09148
35. Florbetaben (18f) (jan/usan/inn)
36. Florbetaben F-18 [orange Book]
37. [18f]bay 94-9172
38. Zk-6013443
39. Q17014149
40. 4-[(e)-2-[4-[2-[2-(2-fluoranylethoxy)ethoxy]ethoxy]phenyl]ethenyl]-n-methylaniline
41. 4-{(e)-2-[4-(2-{2-[2-((18)f)fluoroethoxy]ethoxy}ethoxy)phenyl]ethenyl}-n-methylaniline
Molecular Weight | 358.4 g/mol |
---|---|
Molecular Formula | C21H26FNO3 |
XLogP3 | 4.2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 12 |
Exact Mass | 358.192206 g/mol |
Monoisotopic Mass | 358.192206 g/mol |
Topological Polar Surface Area | 39.7 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 364 |
Isotope Atom Count | 1 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Florbetaben is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate -amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimers Disease (AD) and other causes of cognitive decline.
FDA Label
This medicinal product is for diagnostic use only.
Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimers disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation.
A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.
Following intravenous administration, Neuraceq crosses the blood brain barrier and shows differential retention in brain regions that contain -amyloid deposits. Differences in signal intensity between brain regions showing specific and non-specific Neuraceq uptake form the basis for the image interpretation method.
V09AX06
V - Various
V09 - Diagnostic radiopharmaceuticals
V09A - Central nervous system
V09AX - Other central nervous system diagnostic radiopharmaceuticals
V09AX06 - Florbetaben (18F)
Absorption
Ten minutes after intravenous bolus injection of 300 MBq of Neuraceq in human volunteers, approximately 6% of the injected radioactivity was distributed to the brain. Florbetaben F 18 plasma concentrations declined by approximately 75% at 20 minutes post-injection, and by approximately 90% at 50 minutes.
Route of Elimination
At 12 hours post-administration, approximately 30% of the injected radioactivity had been excreted in urine.
In vitro studies show that metabolism of florbetaben is predominantly catalyzed by CYP2J2 and CYP4F2. Almost all F18 radioactivity in urine was excreted as polar metabolites of florbetaben F18 and only trace amounts of florbetaben F18 were detected.
1 hr
Florbetaben F18 is a F18-labeled stilbene derivative, which binds to -amyloid plaques in the brain. The F 18 isotope produces a positron signal that is detected by a PET scanner.
Related Excipient Companies
Excipients by Applications
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
20
PharmaCompass offers a list of Florbetaben API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Florbetaben manufacturer or Florbetaben supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Florbetaben manufacturer or Florbetaben supplier.
PharmaCompass also assists you with knowing the Florbetaben API Price utilized in the formulation of products. Florbetaben API Price is not always fixed or binding as the Florbetaben Price is obtained through a variety of data sources. The Florbetaben Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Florbetaben F 18 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Florbetaben F 18, including repackagers and relabelers. The FDA regulates Florbetaben F 18 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Florbetaben F 18 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Florbetaben F 18 supplier is an individual or a company that provides Florbetaben F 18 active pharmaceutical ingredient (API) or Florbetaben F 18 finished formulations upon request. The Florbetaben F 18 suppliers may include Florbetaben F 18 API manufacturers, exporters, distributors and traders.
Florbetaben F 18 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Florbetaben F 18 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Florbetaben F 18 GMP manufacturer or Florbetaben F 18 GMP API supplier for your needs.
A Florbetaben F 18 CoA (Certificate of Analysis) is a formal document that attests to Florbetaben F 18's compliance with Florbetaben F 18 specifications and serves as a tool for batch-level quality control.
Florbetaben F 18 CoA mostly includes findings from lab analyses of a specific batch. For each Florbetaben F 18 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Florbetaben F 18 may be tested according to a variety of international standards, such as European Pharmacopoeia (Florbetaben F 18 EP), Florbetaben F 18 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Florbetaben F 18 USP).